Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.55 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9095921 | 0.91 | GABRA1 (0.50) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL6389885 | 0.82 | GABRA1 (0.54) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL27242951 | 0.81 | GABRA1 (0.60) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL29725548 | 0.81 | GABRA1 (0.60) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL1993768 | 0.80 | CYP2C19 (0.43) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL10277803 | 0.80 | KMT2A (0.56) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL622321 | 0.80 | GABRA1 (0.54) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL13271048 | 0.79 | CLEC4M (0.55) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL1665308 | 0.79 | MEN1 (0.67) | GABRA1GABRB2GABRB1GABRA3CLEC4M | |
| SCHEMBL7242460 | 0.79 | TET2 (0.58) | MEN1KMT2AALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-10-12 | — | — | US | disclosed |
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-10-12 | — | — | US | disclosed |
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-10-12 | — | — | US | disclosed |
| US-9505758-B2 | Substituted 1,5-naphthyridines as endonuclease inhibitors | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-11-29 | — | — | US | disclosed |
| US-9505758-B2 | Substituted 1,5-naphthyridines as endonuclease inhibitors | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-11-29 | — | — | US | disclosed |
| US-9505758-B2 | Substituted 1,5-naphthyridines as endonuclease inhibitors | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-11-29 | — | — | US | disclosed |
| EP-2945945-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-08-31 | — | — | EP | disclosed |
| EP-2945945-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-08-31 | — | — | EP | disclosed |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-02-11 | — | — | US | disclosed |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-02-11 | — | — | US | disclosed |
| EP-2483275-B1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2014108408-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014108408-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194432-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| US-20140194432-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| US-20140194432-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| US-8426438-B2 | Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2483275-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Schering Corporation (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| WO-2011041143-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | XDH, CYP27A1, ALAD | GABRA1 4547/4885GABRB2 4682/4885GABRB1 4568/4885 |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM4, CHRM2 | GABRA1 208/4885GABRB2 594/4885GABRB1 457/4885 |
| US-20140194432-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | XDH, CYP27A1, ALAD | GABRA1 4547/4885GABRB2 4682/4885GABRB1 4568/4885 |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | XDH, CYP27A1, ALAD | GABRA1 4547/4885GABRB2 4682/4885GABRB1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.